TLDR
- Serina Therapeutics jumped 39.45% in after-hours trading to $1.78, up from a regular-session close of $1.28.
- The company announced a $15 million private placement closing March 20, with a second $15 million tranche available by April 30.
- Warrant coverage could add up to $33.3 million more, potentially extending runway into the second half of 2027.
- The deal is priced at $2.25 per share — a 68% premium to the March 17 closing price.
- Board director Greg Bailey, who backed Pfizer’s $11.6B Biohaven acquisition and $14B Medivation deal, will become Co-Chairman.
Serina Therapeutics (SER) surged nearly 40% in after-hours trading Wednesday after the small-cap biotech announced a private placement deal that could raise up to $63.3 million in total.
Serina Therapeutics, Inc., SER
The after-hours spike came after markets closed, when Serina revealed the first tranche of $15 million is expected to close on March 20, 2026. A second tranche of up to $15 million is anticipated to close on or before April 30.
The stock went from a regular-session close of $1.28 — down 4.48% on the day — to $1.78 in after-hours trade.
The offering is priced at $2.25 per share, a 68% premium to the March 17 closing price. Each share or pre-funded warrant comes with a half-warrant to buy stock at $5.00 per share. Those warrants have a four-year term and, if fully exercised, could bring in an additional $33.3 million, pushing the total potential raise to $63.3 million.
That kind of runway extension matters for a clinical-stage company. Serina says the proceeds would extend its cash runway into the second half of 2027.
High-Profile Co-Chairman Adds Credibility
The deal is led by Greg Bailey, M.D., a current board member who will now serve as Co-Chairman alongside existing chair Simba Gill, Ph.D.
Bailey brings a strong track record. He was an early backer of Biohaven Ltd., acquired by Pfizer in 2022 for approximately $11.6 billion, and Medivation, also taken out by Pfizer in 2016 for $14 billion.
That history didn’t go unnoticed by investors. Having a name like Bailey attached to a financing round — especially one leading it — can carry real weight in biotech markets.
What the Money is For
Proceeds are earmarked for Serina’s SER-252 registrational study, an ongoing Phase 1b trial targeting advanced Parkinson’s disease. The trial is enrolling patients across sites in Australia and the United States.
SER-252 is being developed under the FDA’s 505(b)(2) regulatory pathway, which CEO Steve Ledger described as “capital-efficient.” The first patient has already been dosed in the study.
Serina expects Cohort 1 safety data to support advancement to Cohort 2 in Q3 2026. Topline results from the single-ascending dose arm are targeted for the first half of 2027.
The drug targets approximately 250,000 advanced Parkinson’s patients in the U.S. and Europe whose symptoms remain inadequately controlled by current treatments.
Despite Wednesday’s post-market jump, SER’s longer-term picture is harder to ignore. The stock has a 52-week range of $1.22 to $7.92 and has declined 71.11% over the past 12 months. Its market cap stands at just $13.65 million, and its RSI sits at 29.86 — deep in oversold territory.
SER closed Wednesday’s regular session at $1.28, down 4.48% on the day.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
